The risk of osteoporotic fractures and its associating risk factors according to the FRAX model in the Iranian patients: a follow-up cohort

Journal of Diabetes & Metabolic Disorders

Bagher Larijani¹  Sara Shirazi²  Fatemeh Zare²  Solmaz Azizian²  Maryam Khoshbin²  Nasrin Nemati²  Farzane Saeidifard¹  Zahra Mohammadi²  Majid Ramezani²  Mehdi Ebrahimi²  Patricia Khashayar²  Abbasali Keshtkar²  Shahnaz Ghafoori¹ 

[1] Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran;Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

关键词: Major osteoporotic fracture;    FRAX;    Fracture;   

Others  :  1136058
DOI  :  10.1186/s40200-014-0093-2

 received in 2014-08-31, accepted in 2014-09-03,  发布年份 2014

【 摘 要 】

Background

The present study is designed to assess the incidence rate of osteoporotic fracture and its risk factors, particularly those used to predict the 10-year risk of osteoporotic fracture in FRAX based on the data gathered through a follow up cohort initiated in 2000.

Methods

The present retrospective cohort was conducted on men and women from 40 to 90 years of age enrolled in the IROSTEOPs study. A phone survey was conducted during 2013 and beginning of 2014 to assess the fractures (traumatic/osteoporotic) occurring at the time of inclusion until the date of the telephone survey, its type and mechanism, and the patient’s age at the time of accident. Survival analysis using Kaplan-Meier product-limit method was performed with the time of fracture as the study outcome.

Results

Final study population consisted of 1233 individuals, translated in to 9133 person years. The incidence rate of osteoporotic fracture was reported to be 359.1 cases in every 10,000 person years. The 10-year Kaplan-Meier estimate of any kind of major osteoporotic fractures for all the subcohort population was 10.75%. Osteoporosis (HR = 0.75), Discordance between femoral neck and spine (HR = 1.45), Diabetes (HR = 1.81), IBD (HR = 1.84), immobility more than 90 days (HR = 2.19), and personal history of fracture (HR = 7.75) had a considerable effect on the 10-year risk of major osteoporotic fractures.

Conclusions

Adding new clinical risk factors to FRAX® may help improve fracture prediction in the Iranian population.

【 授权许可】

   
2014 Ghafoori et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Kanis JA: WHO Technical Report. University of Sheffield, UK; 2007.
• [2]Khashayar P, Aghaei Meybodi HR, Rezai Homami M, Heshmat R, Larijani B: The Prevalence of Osteoporosis in an Iranian Population. J Clin Densitom 2010, 13(1):112.
• [3]Johnell O, Kanis JA: An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006, 17:1726-1733.
• [4]Kanis JA, Johnell O: Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005, 16:220-238.
• [5]Abolhassani F, Moayyeri A, Naghavi M, Soltani A, Larijani B, Shalmani HT, et al.: Incidence and characterisitics of falls leading to hip fracture in Iranian population. Bone 2006, 39:408-413.
• [6]Ahmadi-Abhari S, Moayyeri A, Abolhassani F: Burden of hip fracture in Iran. Calcif Tissue Int 2007, 80:147-153.
• [7]Cummings S, Kelsey J, Nevitt M, O. Dowd K: Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985, 7:178-208.
• [8]Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH: Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002, 162:2217-2222.
• [9]Kanis JA: Assessment of Osteoporosis at the Primary Health-Care Level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK; 2008.
• [10]Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA: Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res 2010, 25:2350-2358.
• [11]Hippisley-Cox J, Coupland C: Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 2009, 339:b4229.
• [12]Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A, Johansson H, Kanis JA: Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 2008, 19:429-435.
• [13]Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M: Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009, 62:105-108.
• [14]Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008, 19:399-428.
• [15]Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA: Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int 1994, 4:277-282.
• [16]Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E: FRAXTM and the assessment of fracture probability in men & women from the UK. Osteoporos. Int. 2008, 19:385-397.
• [17]Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B: Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000, 11:669-674.
• [18]Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM, Hillier TA, Hochberg MC, Vogt MT, Orwoll ES: Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005, 90:2787-2793.
• [19]Kanis JA: Assessment of Osteoporosis at the Primary Health-Care Level. Technical Report. WHO Collaborating Centre. University of Sheffield, Sheffield; 2007.
• [20]Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Glüer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ 3rd, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N: The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007, 18:1033-1046.
• [21]Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Oglesby A: International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 2002, 17:1237-1244.
• [22]Bauer DC: Osteoporotic fractures: ignorance is bliss? Am J Med 2000, 109:338-339.
• [23]Trémollieres FA, Pouillès JM, Drewniak N, Laparra J, Ribot CA, Dargent-Molina P: Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool. J Bone Miner Res 2010, 25(5):1002-1009.
• [24]Sornay-Rendu E, Muñoz F, Delmas PD, Chapurlat RD: The FRAX tool in french women: how well does it describe the real incidence of fracture in the OFELY cohort. J Bone Miner Res 2010, 25:2101-2107.
• [25]Bolland MJ, Siu AT, Mason BH, Horne AM, Ames RW, Grey AB, Gamble GD, Reid IR: Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res 2011, 26:420-427.
• [26]Samelson E, Berry S, Goldberg J, McLean R, Hannan M, Demissie S, Broe K, Kiel D: Comparison of 10-year probability of hip frac- ture predicted by FRAX and observed hip fracture incidence in the Framingham Os- teoporosis Study.J Bone Mires Res 2009, 24(Suppl. 1).
• [27]Runge M, Schacht E: Multifactorial pathogenesis of falls as a basis for multifactorial interventions. J Musculoskelet Neuronal Interact 2005, 5:127-134.
• [28]Dhanwal DK, Dennison EM, Harvey NC, Cooper C: Epidemiology of hip fracture: Worldwide geographic variation. Indian J Orthop 2011, 45(1):15-22.
• [29]González-Macías J, Marin F, Vila J, Díez-Pérez A: Probability of fractures predicted by FRAX® and observed incidence in the Spanish ECOSAP Study cohort. Bone 2012, 50:373-377.
• [30]Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA: Independent Clinical Validation of a Canadian FRAX Tool: Fracture Prediction and Model Calibration. J Bone Miner Res 2010, 25(11):2350-2358.
• [31]Maharlouei N, Khodayari M, Forouzan F, Rezaianzadeh A, Lankarani KB: The incidence rate of hip fracture in Shiraz, Iran during 2008–2010. Arch Osteoporos 2014, 9:165.
• [32]Valizadeh M, Mazloomzadeh S, Azizi R: Epidemiology of hip fractures in Zanjan. Iran. Arch Osteoporos. 2008, 3(1–2):1-5.
• [33]Hui SL, Slemenda CW, Johnston CC: Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988, 81:1804-1809.
• [34]Kanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey E: FRAX® and its applications to clinical practice. Bone 2009, 44:734-743.
• [35]Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312:1254-1259.
• [36]Pluskiewicz W, Adamczyk P, Franek E, Leszczynski P, Sewerynek E, Wichrowska H, Napiorkowska L, Kostyk T, Stuss M, Stepien-Klos W, Golba KS, Drozdzowska B: Ten-year probability of osteoporotic fracture in 2012 Polish women assessed by FRAX and nomogram by Nguyen et al.: Conformity between methods and their clinical utility. Bone 2010, 46:1661-1667.
• [37]Melton LJ 3rd, Amin S: Is there a specific fracture 'cascade'? Bonekey Rep 2013, 26(2):367.
• [38]Leslie WD1, Morin SN, Lix LM, Majumdar SR: Does diabetes modify the effect of FRAX risk factors for predicting majorosteoporotic and hip fracture?Osteoporos Int 2014, Epub ahead of print.
• [39]Kanis JA, Borgström F, Compston J, Dreinhöfer K, Nolte E, Jonsson L, Lems WF, McCloskey EV, Rizzoli R, Stenmark J: SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos 2013, 8(1–2):144.
• [40]Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA: Osteoporosis in the European Union: medical management, epidemiology and economic burden: A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013, 8(1–2):136.
• [41]Davison KS, Siminoski K, Chik C, Jen H, Warshawski R, Lee K: Impact of height loss due to vertebral fractures on body mass index. J Bone Miner Res 2003, 18(Suppl 2):S243.
• [42]Hernández JL, Marin F, González-Macías J, Díez-Pérez A, Vila J, Giménez S, Galán B, Arenas MS, Suárez F, Gayola L, Guillén G, Sagredo T, Belenguer R, Moron A, Arriaza E: Discriminative capacity of calcaneal quantitative ultrasound and fracture risk factors in postmenopausal women with osteoporotic fractures. Calcif Tissue Int 2004, 74:357-365.
• [43]LeBlanc KE, Muncie HL Jr, LeBlanc LL: Hip fracture: diagnosis, treatment, and secondary prevention. Am Fam Physician 2014, 89(12):945-951.
• [44]Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR: The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998, 128:793-800.
• [45]Midanik LT: Validity of self-reported alcohol use: a literature review and assessment. Br J Addict 1998, 83:1019-1030.